Langer, Ciechanover godfather the latest AI upstart; Ipsen forges $446M AML development pact
There’s a new AI player jumping into the drug discovery game. And they have some high-powered scientific advisors in their corner.
Tel Aviv-based Quris has built what it calls a “patient-on-a-chip” AI platform that it’s touting as a way to circumvent unreliable animal testing with a more efficient way to judge safety and efficacy. Animal testing, particularly involving mice, has proven a notoriously unreliable way to do preclinical testing — though it is well-established with regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
